Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
$15.09
+5.7%
$12.95
$4.81
$27.50
$506.93MN/A324,882 shs154,165 shs
Neumora Therapeutics, Inc. stock logo
NMRA
Neumora Therapeutics
$1.73
-1.7%
$1.47
$0.61
$17.19
$285.02M2.91697,789 shs236,535 shs
Precigen, Inc. stock logo
PGEN
Precigen
$4.51
-0.9%
$2.16
$0.65
$4.82
$1.36B1.8716.92 million shs9.09 million shs
Scilex Holding Company stock logo
SCLX
Scilex
$17.76
-2.6%
$11.94
$3.60
$42.53
$126.80M1.32258,505 shs70,401 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
+5.75%+5.30%-2.58%+20.43%+1,508,999,900.00%
Neumora Therapeutics, Inc. stock logo
NMRA
Neumora Therapeutics
-1.70%+6.79%-16.83%+143.90%-85.05%
Precigen, Inc. stock logo
PGEN
Precigen
-0.88%+7.89%+160.69%+241.67%+299.12%
Scilex Holding Company stock logo
SCLX
Scilex
-2.58%-5.88%+37.25%+246.20%-54.29%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
2.6308 of 5 stars
3.50.00.00.03.41.70.6
Neumora Therapeutics, Inc. stock logo
NMRA
Neumora Therapeutics
2.6298 of 5 stars
3.13.00.00.02.72.50.6
Precigen, Inc. stock logo
PGEN
Precigen
4.0788 of 5 stars
3.40.00.04.73.13.30.6
Scilex Holding Company stock logo
SCLX
Scilex
2.2461 of 5 stars
3.32.00.00.02.71.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
3.00
Buy$37.63149.34% Upside
Neumora Therapeutics, Inc. stock logo
NMRA
Neumora Therapeutics
2.22
Hold$7.14312.88% Upside
Precigen, Inc. stock logo
PGEN
Precigen
2.80
Moderate Buy$8.2582.93% Upside
Scilex Holding Company stock logo
SCLX
Scilex
2.50
Moderate Buy$455.002,461.94% Upside

Current Analyst Ratings Breakdown

Latest SCLX, NMRA, MBX, and PGEN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/19/2025
Precigen, Inc. stock logo
PGEN
Precigen
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform
8/19/2025
Precigen, Inc. stock logo
PGEN
Precigen
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Outperform ➝ Market Outperform$6.00 ➝ $8.00
8/19/2025
Precigen, Inc. stock logo
PGEN
Precigen
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$8.50
8/15/2025
Precigen, Inc. stock logo
PGEN
Precigen
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeUnderweight ➝ Neutral
8/13/2025
Precigen, Inc. stock logo
PGEN
Precigen
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$6.00
8/5/2025
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$38.00
7/16/2025
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$38.00
7/16/2025
Neumora Therapeutics, Inc. stock logo
NMRA
Neumora Therapeutics
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$4.00 ➝ $5.00
6/12/2025
Precigen, Inc. stock logo
PGEN
Precigen
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$6.00
(Data available from 8/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
N/AN/AN/AN/AN/AN/A
Neumora Therapeutics, Inc. stock logo
NMRA
Neumora Therapeutics
N/AN/AN/AN/A$1.13 per shareN/A
Precigen, Inc. stock logo
PGEN
Precigen
$3.92M342.82N/AN/A($0.12) per share-37.58
Scilex Holding Company stock logo
SCLX
Scilex
$56.59M2.18N/AN/A($35.80) per share-0.50
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
N/A-$4.54N/AN/AN/AN/AN/AN/AN/A
Neumora Therapeutics, Inc. stock logo
NMRA
Neumora Therapeutics
-$243.79M-$1.57N/AN/AN/AN/A-98.95%-87.68%11/11/2025 (Estimated)
Precigen, Inc. stock logo
PGEN
Precigen
-$126.24M-$0.42N/AN/AN/A-2,868.66%-842.83%-78.98%11/13/2025 (Estimated)
Scilex Holding Company stock logo
SCLX
Scilex
-$72.81M-$29.02N/AN/AN/A-179.12%N/A-109.95%11/12/2025 (Estimated)

Latest SCLX, NMRA, MBX, and PGEN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025Q2 2025
Scilex Holding Company stock logo
SCLX
Scilex
-$4.55-$7.42-$2.87-$7.42$26.25 million$9.90 million
8/12/2025Q2 2025
Precigen, Inc. stock logo
PGEN
Precigen
-$0.14-$0.11+$0.03-$0.09$0.67 million$0.86 million
8/6/2025Q2 2025
Neumora Therapeutics, Inc. stock logo
NMRA
Neumora Therapeutics
-$0.38-$0.33+$0.05-$0.33N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
N/AN/AN/AN/AN/A
Neumora Therapeutics, Inc. stock logo
NMRA
Neumora Therapeutics
N/AN/AN/AN/AN/A
Precigen, Inc. stock logo
PGEN
Precigen
N/AN/AN/AN/AN/A
Scilex Holding Company stock logo
SCLX
Scilex
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
N/AN/AN/A
Neumora Therapeutics, Inc. stock logo
NMRA
Neumora Therapeutics
0.11
10.54
10.54
Precigen, Inc. stock logo
PGEN
Precigen
N/A
2.71
2.71
Scilex Holding Company stock logo
SCLX
Scilex
N/A
0.11
0.10

Institutional Ownership

CompanyInstitutional Ownership
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
N/A
Neumora Therapeutics, Inc. stock logo
NMRA
Neumora Therapeutics
47.65%
Precigen, Inc. stock logo
PGEN
Precigen
33.51%
Scilex Holding Company stock logo
SCLX
Scilex
69.67%

Insider Ownership

CompanyInsider Ownership
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
52.19%
Neumora Therapeutics, Inc. stock logo
NMRA
Neumora Therapeutics
26.80%
Precigen, Inc. stock logo
PGEN
Precigen
47.10%
Scilex Holding Company stock logo
SCLX
Scilex
7.94%
CompanyEmployeesShares OutstandingFree FloatOptionable
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
3633.59 millionN/AN/A
Neumora Therapeutics, Inc. stock logo
NMRA
Neumora Therapeutics
108161.95 million118.54 millionOptionable
Precigen, Inc. stock logo
PGEN
Precigen
190297.97 million157.63 millionOptionable
Scilex Holding Company stock logo
SCLX
Scilex
806.96 million6.40 millionOptionable

Recent News About These Companies

Scilex (NASDAQ:SCLX) Trading Up 10.1% - Time to Buy?
SCLX Scilex Holding Company - Seeking Alpha
Scilex Holding Stock Price History

New MarketBeat Followers Over Time

Media Sentiment Over Time

MBX Biosciences stock logo

MBX Biosciences NYSE:MBX

$15.09 +0.82 (+5.75%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$15.04 -0.05 (-0.33%)
As of 08/29/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.

Neumora Therapeutics stock logo

Neumora Therapeutics NASDAQ:NMRA

$1.73 -0.03 (-1.70%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$1.71 -0.02 (-1.16%)
As of 08/29/2025 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

Precigen stock logo

Precigen NASDAQ:PGEN

$4.51 -0.04 (-0.88%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$4.62 +0.12 (+2.55%)
As of 08/29/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

Scilex stock logo

Scilex NASDAQ:SCLX

$17.76 -0.47 (-2.58%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$17.78 +0.02 (+0.14%)
As of 08/29/2025 07:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California.